Weekly FDA Roundup: Hormone Therapy Gets a New Label, Botulism Stalks the Supplement Aisle — Week of Feb 7–14, 2026

The week of Feb 7–14, 2026 delivered one of the most consequential sets of FDA actions in recent memory: a sweeping rewrite of menopausal hormone therapy labeling that has already begun straining supply chains, a first-of-its-kind device approval for the deadliest common cancer, and a food safety cluster so concentrated it warrants attention from every company sourcing or selling shelf-stable supplements and cold-pressed beverages. Across 82 total items — 51 recalls, 12 warning letters, 14 notices, 2 safety alerts, and 3 press releases — the through-line was unmistakable: the FDA under Commissioner Makary is moving fast on both approvals and enforcement.

---

By the Numbers

Category	Count
Total items	82
Recalls	51
Warning letters	12
Federal Register notices	14
Safety alerts	2
Press releases	3
Critical food safety hazards	Clostridium botulinum (12 SKUs), pathogenic bacteria (7 products)
Enforcement concentration	All 12 warning letters published Feb 10

---

Lead Story: Hormone Therapy's Black Box Warning Is Gone

On February 12, FDA approved labeling changes for six menopausal hormone therapy (MHT) products, formally removing risk statements related to cardiovascular disease, breast cancer, and probable dementia from the boxed warning — the agency's most emphatic safety signal — that has appeared on these products since 2003.

This is not a routine label update. The boxed warning's existence for over two decades has been widely credited with suppressing MHT prescribing: in 2020, roughly 41 million U.S. women were ages 45–64, yet only about 2 million received a hormone therapy prescription. HHS Secretary RFK Jr. and Commissioner Makary framed the removal as a course correction based on accumulated evidence, particularly data showing that women who initiate HRT within 10 years of menopause onset have reduced all-cause mortality and fracture risk.

This first batch of six covers all four MHT categories — systemic combination therapy, systemic estrogen-alone, progestogen-alone, and topical vaginal estrogen. Twenty-nine companies in total have submitted proposed labeling changes, with further approvals expected in coming weeks.

---

Key Developments

Sea Moss Gets a Botulism Problem

Diva Fam Inc issued recalls across at least 12 distinct SKUs of its "Sea Moss Gel Superfood" 16 FL OZ glass jars due to potential contamination with Clostridium botulinum. Affected flavors include Soursop, Mango, Orange, Blue Spirulina and Raspberry, Pineapple, Apple and Cinnamon, Passion Fruit, Strawberry, Wildcrafted, 5 Blend in 1, and additional varieties. These are sold as dietary supplements and specialty foods.

C. botulinum is not a routine recall hazard — it produces one of the most potent toxins known, can cause life-threatening paralysis, and is associated with high-pH, low-oxygen environments like improperly sealed glass jars. The scope here (12+ flavors from a single brand) points to a systemic production or preservation failure, not an isolated incident. The recalls are Class II, meaning FDA has assessed the probability of serious adverse health consequences as remote — but given the pathogen involved, consumers should treat any uncertainty as a reason to discard product immediately.

For supplement and specialty food companies: Sea moss gel has grown rapidly as a wellness product. This recall is a signal that the category needs tighter HACCP controls, particularly around water activity, pH testing, and anaerobic spoilage monitoring.

JUICE from the Raw: Seven Products, One Root Cause

JUICE from the Raw recalled at least seven distinct cold-pressed juice products during this period — including cashew milk, cashew coffee milk, spicy lemonade, pineapple mint, detox greens, sweet greens, and "upbeat" juice — due to potential contamination with pathogenic bacteria linked to under-processing. The root cause, noted explicitly in multiple recall entries, is a failure to achieve adequate thermal or non-thermal processing parameters for products sold as shelf-stable or refrigerated.

Seven simultaneous product recalls from a single producer represents a facility-level control failure. Cold-pressed juice companies have historically argued that high-pressure processing (HPP) or refrigeration is sufficient to address pathogen risk; FDA's enforcement posture has consistently been that HACCP planning must account for the full range of hazards for the specific product and distribution model.

First-of-Its-Kind Device Clears PMA for Pancreatic Cancer

Novocure's Optune Pax became the first FDA-approved device for locally advanced pancreatic cancer on February 12, clearing the premarket approval (PMA) pathway — the agency's most rigorous review track for devices. The device delivers Tumor Treating Fields (TTFields) via adhesive patches worn on the abdomen, physically disrupting cancer cell division without the systemic toxicity of chemotherapy.

In a randomized controlled pivotal trial, adding TTFields to standard gemcitabine and nab-paclitaxel chemotherapy extended overall survival by approximately two months compared to chemotherapy alone. That may sound modest in isolation, but for a cancer that kills nearly 80% of patients within a year of diagnosis — accounting for 3.3% of diagnoses but a disproportionate share of cancer deaths — any validated survival extension achieved through a non-invasive, at-home wearable device is clinically significant. Novocure received Breakthrough Device designation in December 2024.

FDA Launches BHA Reassessment

On February 10, FDA issued a formal Request for Information (RFI) on butylated hydroxyanisole (BHA), a synthetic antioxidant used since 1958 to prevent oxidative spoilage in fats and oils. BHA appears across a wide range of packaged foods: breakfast cereals, frozen meals, cookies, ice cream, candy, and meat products. The RFI seeks updated data on current use levels, exposure estimates, and safety.

FDA listed BHA as GRAS in 1958 and approved it as a food additive in 1961. The reassessment signals the agency is reconsidering that determination, likely accelerated by state-level pressure — a West Virginia law banning products containing BHA (along with other ingredients) takes effect January 1, 2028. The RFI docket is FDA-2026-N-0302; comments are open.

For food manufacturers: This is not a ban, but it is an early warning. Companies using BHA as a preservative in multi-ingredient formulations should begin mapping exposure across their portfolio and evaluating reformulation options with tocopherols, rosemary extract, or other alternatives now, before any regulatory action forces a rushed transition.

Twelve Warning Letters Land on the Same Monday

All 12 warning letters for the week were published February 10, covering:

• Three fertility/HCT centers — Central Coast Multispecialty Medical Group, Conceive Fertility Center, and Louisville Reproductive Center all received letters citing violations of 21 CFR Part 1271, the regulations governing human cells, tissues, and cellular and tissue-based products (HCT/Ps). This level of simultaneous HCT enforcement across separate facilities suggests coordinated inspection activity.
• Boothwyn Pharmacy (compounding) and Bio-Medical Pharmaceutical Manufacturing — CGMP violations for finished pharmaceuticals. Boothwyn's letter specifically cited tirzepatide-related compounding issues.
• Maui Seafood LLC — Seafood HACCP and CGMP violations for adulterated ready-to-eat product.
• ProDx Health — Marketing a Human Immunodeficiency Virus (HIV) diagnostic test without a valid IDE or PMA. Devices reaching market without the required premarket authorization represent one of FDA's highest-priority enforcement categories.
• Two tobacco retailers (niqpouches.com and BNC Distribution) — Violations of the Family Smoking Prevention and Tobacco Control Act.

---

The Bigger Picture

This week's data fits a pattern visible across the past 60 days: recalls are the dominant enforcement instrument (194 out of 446 total items), while warning letters (101 over the same period) remain a consistent enforcement pressure particularly concentrated in CGMP and compounding. The simultaneous release of 12 warning letters on a single day — all dated February 10 — matches a practice seen in prior weeks where FDA batches enforcement letters for coordinated publication.

The allergen picture this week reflects ongoing label control failures — undeclared milk, soy, egg, almonds, and sulfites appear across more than 10 distinct recall events. For food manufacturers, the sheer frequency of allergen recalls underscores that label verification at the point of production, not just at label design, remains a persistent gap.

The quinine story is less discussed but worth noting: BarbaCuban recalled five distinct condiment and sauce products (Everything Sauce, Ram Air Red Zesty Ketchup, 90 Miles to Mojo Marinade, Cubama White Truffle Sauce, and Havana Gold beverage) for undeclared quinine. Quinine is a prescription-only drug ingredient with a narrow therapeutic window; its presence in food products is both a labeling violation and a potential drug interaction risk.

---

What to Watch

• MHT labeling wave: 23 more companies have submitted proposed changes. Expect additional approval batches over the coming weeks as FDA works through the queue. Monitor for any DOGE-related processing delays.
• BHA comment period: Docket FDA-2026-N-0302 is open. Food manufacturers using BHA should file data to shape the record — the outcome of this RFI will inform any rulemaking.
• JUICE from the Raw: Seven simultaneous recalls from one facility typically precede a consent decree or import alert action. Watch for escalation.
• 2026–2027 flu vaccine strain composition: VRBPAC meeting announced for this period will set the influenza vaccine composition for the coming season. Vaccine manufacturers and distributors should track the meeting date and preliminary recommendations.

---

Policy Canary monitors FDA changes for your specific products — by name, by ingredient. Join the pilot program.